Form 4: Repligen Director Martin D. Madaus Reports Stock and Option Awards

Director Martin D. Madaus reports the acquisition of restricted stock units and stock options in Repligen Corporation.

Summary

• Martin D. Madaus, a director of Repligen Corporation, filed a Form 4 disclosing changes in beneficial ownership.
• On May 15, 2025, Madaus acquired 973 restricted stock units (RSUs), each representing a contingent right to receive one share of Repligen's common stock.
• These RSUs vest on the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders.
• Madaus also acquired 1,800 stock options with an exercise price of $123.26, vesting on the same date as the RSUs and expiring on May 15, 2035.
• Following these transactions, Madaus directly owns 1,800 derivative securities and indirectly owns 5,586 shares of common stock through a spouse's trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The filing itself is a routine disclosure, but the acquisition of shares and options by a director can be interpreted as a sign of confidence in the company's future.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the RSUs and stock options is contingent on future events (annual meeting or date certain).

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and life sciences sectors.
• Companies like Danaher, Thermo Fisher Scientific, and Sartorius also utilize similar equity-based compensation plans to align management's interests with those of shareholders.
• The vesting schedules and exercise prices are generally in line with industry standards, designed to incentivize long-term value creation.

Stakeholder Impact

• The transactions reported in the Form 4 may have a minor positive impact on shareholder sentiment, as they reflect a director's increased investment in the company.

Next Steps

• The restricted stock units will vest on the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders.
• The stock options will become exercisable on the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders.

Key Dates

Keywords

Form 4, Repligen, Director, Madaus, Stock Options, Restricted Stock Units, Beneficial Ownership, RGEN